No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
www.taslypharma.comNo one on the platform currently holds 600535.SS.
No tracked institution reports a position in 600535.SS as of their last filing.
No one on the platform has traded 600535.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.7% | — | — | — | ||
| Rev. Growth % | -3.1% | -9.5% | ||||
| Profit Margin % | 13.4% | 12.7% | 10.3% | |||
| Free Cash Flow Margin % | 12.7% | 20.3% | 11.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.6B | -1.9% | $0.88 | $0.79–$0.94 | — | 3 |
| 2027 | $9.4B | +8.6% | $1.03 | $0.93–$1.11 | — | 3 |
| 2028 | $10.2B | +8.7% | $1.19 | $1.08–$1.50 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-14 | $0.40 | $0.35 | -12.2% |
| 2026-04-24 | $0.26 | $0.25 | -3.8% |
| 2026-02-06 | $0.09 | $0.09 | +0.0% |
| 2025-10-24 | $0.17 | $0.14 | -17.4% |
| 2025-08-15 | $0.25 | $0.23 | -8.0% |
| 2025-04-28 | $0.22 | $0.21 | -4.5% |
| 2025-02-24 | $0.19 | $0.08 | -57.9% |
| 2024-10-25 | $0.21 | $0.12 | -42.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600535.SSTasly Pharmaceutical Group Co., Ltd | $13.90 | -0.50% | $20.8B | — |
| 000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. | $17.45 | +0.29% | $20.9B | — |
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.49 | +0.54% | $26.1B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.59 | -0.28% | $21.9B | — |
| 300558.SZBetta Pharmaceuticals Co., Ltd. |
| $46.92 |
| +1.54% |
| $19.9B |
| — |
| 300723.SZApicHope Pharmaceutical Co., Ltd | $33.74 | +1.23% | $15.2B | — |
| 600062.SSChina Resources Double-Crane Pharmaceutical Co.,Ltd. | $15.82 | -1.00% | $16.4B | — |
Source: Financial Modeling Prep · peers by sector/industry